Stock 0A87 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Takeda Pharmaceutical Company Limited London S.E.

Equities

0A87

US8740602052

Market Closed - London S.E.
Other stock markets
 16:28:45 18/06/2024 BST 		After market 18:25:26
12.74 USD -2.52% Intraday chart for Takeda Pharmaceutical Company Limited 12.6 -1.06%
06-18 Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP MT
06-18 Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting
AQ
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat
AQ
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
BU
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K
PU
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
BU
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
BU
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
BU
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K
PU
TAKEDA PHARMACEUTICAL : Form 6 K
PU
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K
PU
Takeda Pharmaceutical - Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan
AQ
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
BU
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
BU
Takeda Pharmaceutical : Other items which are provided electronically
PU
TAKEDA PHARMACEUTICAL : Form 6-K
PU
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
AQ
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
BU
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
BU
Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
AQ
Takeda Pharmaceutical, Announces full-year 2023 results and outlook for 2024 Emphasizes commitment to late-stage pipeline development and core operating margin improvement
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. 0A87 Stock
  5. News Takeda Pharmaceutical Company Limited
  6. Press Releases